Advanced Flower Capital (AFCG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Executive summary
The annual meeting will be held virtually on May 28, 2026, with shareholders able to vote online, by phone, or by mail.
Shareholders as of March 30, 2026, are eligible to vote on director elections and auditor ratification.
The Board recommends voting for all director nominees and for the ratification of the independent auditor.
Voting matters and shareholder proposals
Two Class III directors, Alexander Frank and Marnie Sudnow, are nominated for election to serve until 2029.
Ratification of CohnReznick LLP as the independent registered public accounting firm for 2026 is up for vote.
Shareholders may submit proposals for the 2027 annual meeting by December 29, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The Board consists of five members, four of whom are independent under Nasdaq and 1940 Act rules.
Board leadership includes a non-independent Chairman and a lead independent director.
Three standing committees (Audit, Compensation, Nominating & Corporate Governance) are composed solely of independent directors.
Annual self-evaluations and succession planning are conducted, and director diversity is considered in nominations.
Directors are limited to serving on no more than four other public company boards unless approved.
Latest events from Advanced Flower Capital
- Q1 2026 net investment income was $4.8M, NAV per share rose to $7.90, and a $5M buyback was authorized.AFCG
Q1 20267 May 2026 - BDC conversion expanded investment scope; $1.4B pipeline, $366M principal outstanding in 2025.AFCG
Q4 202527 Apr 2026 - Cannabis lending platform delivers 20% yields and strong dividends amid rapid industry growth.AFCG
Investor presentation24 Apr 2026 - Vote on director elections and auditor ratification at the May 2026 annual meeting.AFCG
Proxy filing17 Apr 2026 - Q2 2025 net loss of $13.2M, $3.4M distributable earnings, and BDC conversion planned.AFCG
Q2 202510 Mar 2026 - Q2 net income reached $16.4M as the company became a pure-play cannabis lender.AFCG
Q2 20242 Feb 2026 - Q3 2024 earnings met targets, with strong originations and higher risk post-CRE spin-off.AFCG
Q3 202414 Jan 2026 - Exceeded origination targets, delivered strong yields, and maintained a robust pipeline.AFCG
Q4 202424 Dec 2025 - REIT lender to cannabis sector files $1B shelf registration for flexible equity and debt offerings.AFCG
Registration Filing16 Dec 2025